|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
51.18(B) |
Last
Volume: |
2,329,383 |
Avg
Vol: |
1,913,313 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
216,903 |
279,977 |
305,346 |
572,908 |
Total Sell Value |
$29,188,685 |
$36,914,107 |
$39,804,708 |
$69,867,568 |
Total People Sold |
7 |
10 |
14 |
15 |
Total Sell Transactions |
15 |
27 |
47 |
80 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Blackford Quentin S. |
Chief Operating Officer |
|
2021-09-08 |
4 |
AS |
$545.87 |
$4,192,846 |
D/D |
(7,681) |
30,261 |
|
-21% |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2021-09-07 |
4 |
AS |
$545.41 |
$320,156 |
D/D |
(587) |
13,933 |
|
-22% |
|
Murphy Patrick Michael |
EVP, Chief Legal Officer |
|
2021-08-26 |
4 |
AS |
$517.24 |
$258,620 |
D/D |
(500) |
17,241 |
|
-9% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-08-23 |
4 |
AS |
$513.41 |
$556,678 |
D/D |
(1,078) |
49,085 |
|
2% |
|
Dahut Karen M |
Director |
|
2021-08-11 |
4 |
A |
$0.00 |
$0 |
I/I |
387 |
387 |
|
- |
|
Dahut Karen M |
Director |
|
2021-08-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(387) |
1,691 |
|
- |
|
Selvaraj Shelly Ramasamy |
SVP Information Technology |
|
2021-08-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
250 |
15,886 |
|
- |
|
Balo Andrew K |
* |
|
2021-08-03 |
4 |
AS |
$512.19 |
$1,422,247 |
I/I |
(2,757) |
10,652 |
|
9% |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2021-07-30 |
4 |
AS |
$476.70 |
$5,761,873 |
D/D |
(12,087) |
70,554 |
|
10% |
|
Murphy Patrick Michael |
EVP, Chief Legal Officer |
|
2021-07-26 |
4 |
AS |
$458.79 |
$229,395 |
D/D |
(500) |
17,741 |
|
21% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-07-23 |
4 |
AS |
$450.82 |
$487,897 |
D/D |
(1,079) |
50,163 |
|
22% |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2021-07-16 |
4 |
AS |
$450.00 |
$180,000 |
D/D |
(400) |
12,586 |
|
38% |
|
Balo Andrew K |
* |
|
2021-07-06 |
4 |
AS |
$428.51 |
$1,279,228 |
I/I |
(2,974) |
13,409 |
|
41% |
|
Murphy Patrick Michael |
EVP, Chief Legal Officer |
|
2021-06-28 |
4 |
AS |
$431.49 |
$215,745 |
D/D |
(500) |
18,241 |
|
45% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-06-23 |
4 |
AS |
$424.84 |
$460,651 |
D/D |
(1,079) |
51,242 |
|
44% |
|
Skyler Jay S |
Director |
|
2021-06-22 |
4 |
AS |
$425.45 |
$8,527,406 |
I/I |
(20,000) |
13,968 |
|
33% |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2021-06-11 |
4 |
AS |
$401.09 |
$160,436 |
D/D |
(400) |
12,986 |
|
37% |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2021-06-09 |
4 |
AS |
$395.00 |
$8,988,225 |
D/D |
(22,755) |
82,641 |
|
40% |
|
Augustinos Nicholas |
Director |
|
2021-06-03 |
4 |
AS |
$366.99 |
$295,794 |
D/D |
(806) |
3,110 |
|
40% |
|
Balo Andrew K |
* |
|
2021-06-03 |
4 |
AS |
$375.00 |
$896,625 |
I/I |
(2,391) |
16,383 |
|
40% |
|
Balo Andrew K |
* |
|
2021-06-03 |
4 |
A |
$0.00 |
$0 |
I/I |
18,774 |
18,774 |
|
- |
|
Balo Andrew K |
* |
|
2021-06-03 |
4 |
AS |
$0.00 |
$0 |
D/D |
(18,774) |
16,533 |
|
40% |
|
Blackford Quentin S. |
Chief Operating Officer |
|
2021-05-28 |
4 |
AS |
$375.00 |
$2,708,625 |
D/D |
(7,223) |
37,942 |
|
47% |
|
Murphy Patrick Michael |
EVP, Chief Legal Officer |
|
2021-05-26 |
4 |
AS |
$350.00 |
$175,000 |
D/D |
(500) |
18,741 |
|
48% |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2021-05-25 |
4 |
S |
$354.79 |
$518,348 |
D/D |
(1,461) |
13,386 |
|
-56% |
|
2279 Records found
|
|
Page 12 of 92 |
|
|